Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

NCT03565068
View directory record Official record
Conditions
Schizophrenia
Interventions
MK-8189, Placebo, Background AAP Therapy
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 15, 2026, 10:29 PM EDT
Not listed No phase listed Observational

DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics

NCT00752960
View directory record Official record
Conditions
Psychoses
Interventions
Not listed
Lead sponsor
Genomas, Inc
Industry
Eligibility
18 Years to 59 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Hartford, Connecticut • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 16, 2008 · Synced Oct 15, 2026, 10:29 PM EDT
Not listed Not applicable Interventional

Comparing Cognitive Remediation Approaches for Schizophrenia

NCT04123223
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive Remediation, Computer Games
Behavioral
Lead sponsor
Wesleyan University
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Hartford, Connecticut • Middletown, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia

NCT01129882
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
52
States / cities
Bellevue, California • Garden Grove, California • Glendale, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 1 Interventional

A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

NCT00567203
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-3463275, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Glendale, California • Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 2, 2008 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

Systematic Evaluation of Antiviral Medication in Schizophrenia

NCT00514449
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
Konasale Prasad
Other
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Detroit, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Not applicable Interventional

Online Family Support and Education for Schizophrenia

NCT00046085
View directory record Official record
Conditions
Schizophrenia
Interventions
Online Family Education, Customary care
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 3 Interventional

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714661
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
38
States / cities
Tucson, Arizona • Anaheim, California • Bellflower, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Not applicable Interventional

Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar or Schizophrenia Illness

NCT03935854
View directory record Official record
Conditions
Obesity, Ketogenic Dieting, Metabolic Syndrome, Bipolar Disorder, Schizophrenia, Weight Gain, Psychotropic Agents Causing Adverse Effects in Therapeutic Use, Brain Metabolic Disorder
Interventions
LCHF, Ketogenic Diet
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Adult Study Oxytocin - fMRI

NCT02566356
View directory record Official record
Conditions
Schizophrenia, Oxytocin, Social Cognition, Functional Magnetic Resonance Imaging (fMRI)
Interventions
Oxytocin, Saline Nasal Spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 1 Interventional

A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder

NCT02636842
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Aripiprazole Lauroxil
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Cerritos, California • Lemon Grove, California • Oakland, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 15, 2026, 10:29 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Brain Stimulation on Cognition, Oscillations and GABA Levels in Schizophrenia

NCT04267003
View directory record Official record
Conditions
Schizophrenia
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 47 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Social Cognition Training in Schizophrenia

NCT00587561
View directory record Official record
Conditions
Schizophrenia
Interventions
Social Cognition Interaction Training, WLC
Behavioral
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 4 Interventional Results available

Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder

NCT03526354
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Substance Use Disorders
Interventions
Brexpiprazole, Treatment as Usual
Drug · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Augusta, Georgia • Boston, Massachusetts • Worcester, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 3 Interventional

CAFE Comparison of Atypicals in First Episode of Psychosis

NCT00034892
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
Interventions
Olanzapine, risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
24
States / cities
Stanford, California • Miami, Florida • Atlanta, Georgia + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 15, 2026, 10:29 PM EDT
Withdrawn Not applicable Interventional

Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia

NCT02661347
View directory record Official record
Conditions
Schizophrenia, Schizophreniform, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
Interventions
Risperidone, tDCS
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 15, 2026, 10:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Cell Injury in Patients With A First Episode of Psychosis

NCT00070889
View directory record Official record
Conditions
Psychoses
Interventions
Not listed
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
12 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 15, 2026, 10:29 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Anticholinergic Deprescription in Schizophrenia

NCT06562608
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Anticholinergic Deprescription, No Anticholinergic Deprescription
Drug
Lead sponsor
Deepak K. Sarpal, M.D.
Other
Eligibility
40 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Early Phase 1 Interventional

Cognitive Effects of Nimodipine in Patients With Schizophrenia

NCT03671525
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
Nimodipine, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 15, 2026, 10:29 PM EDT
Not yet recruiting Not applicable Interventional

Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling

NCT06748950
View directory record Official record
Conditions
Schizophrenia, Schizophrenia and Related Disorders, Bipolar Disorder, Bipolar and Related Disorders, Major Depressive Disorder, Major Depression Severe, Ketogenic Dieting, Ketosis, Metabolic Disease, Metabolic Syndrome
Interventions
LCHF Ketogenic Diet, Diet-as-Usual (DAU)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Not applicable Interventional Results available

Mobile After-Care Intervention to Support Post-Hospital Transition (MACS)

NCT03769493
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Mobile After-Care Support (MACS) app
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

NCT03238326
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
17
States / cities
Dothan, Alabama • Anaheim, California • Culver City, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 15, 2026, 10:29 PM EDT
Withdrawn Phase 3 Interventional

Zyprexa and Task Engagement in Schizophrenia

NCT00440843
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Olanzapine (Zyprexa), Typicals
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

D-serine and Cognitive Remediation in Schizophrenia

NCT02156908
View directory record Official record
Conditions
Schizophrenia
Interventions
D-serine
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 64 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 15, 2026, 10:29 PM EDT